Unity Biotechnology, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 8 rows in 2025. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2025-03-28: Reporting owner Nguyen Alexander Hieu; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2025-03-28: Reporting owner Sullivan Lynne Marie; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2025-03-28: Reporting owner Ghosh Anirvan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2025-03-08: Reporting owner Hashad Yehia; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-03-28 | Nguyen Alexander Hieu Officer (CLO and Head of Ops) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +73,000 73,000 owned after | $1.67 exercise price | 2025-03-31 | |
| 2025-03-28 | Sullivan Lynne Marie Officer (CFO & Head of Corp. Dev.) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +106,000 106,000 owned after | $1.67 exercise price | 2025-03-31 | |
| 2025-03-28 | Ghosh Anirvan Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +286,000 286,000 owned after | $1.67 exercise price | 2025-03-31 | |
| 2025-03-08 | Hashad Yehia Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $1.68 exercise price | 2025-03-10 | |
| 2025-01-22 | Nguyen Alexander Hieu Officer (CLO and Head of Ops) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $2.09 exercise price | 2025-01-23 | |
| 2025-01-22 | Sullivan Lynne Marie Officer (CFO & Head of Corp. Dev.) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $2.09 exercise price | 2025-01-23 | |
| 2025-01-22 | Ghosh Anirvan Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +450,000 450,000 owned after | $2.09 exercise price | 2025-01-23 | |
| 2025-01-06 | Grossi Federico Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.78 exercise price | 2025-01-07 |